Gideon Strategic Partners

Dallas Biotech Secures $50M Series D Funding To Combat Rare Hidden Killer in Joint Replacements

by | Jul 16, 2024
The $50 million funding will support the commercial launch of Osteal Therapeutics' pioneering combination drug/device therapy targeting biofilm infections, which are notoriously difficult to eradicate.
MORE
Protecting your privacy. We have strengthened our Privacy Policy to better protect you. This Policy includes our use of cookies to give you the best online experience and provide functionality essential to our services. By clicking ‘I Accept’ or by continuing to use our website, you are consenting to our Privacy Policy.